Identification
Personal identification
- Full name
- Ana Alexandra Duarte Martins da Silva
Citation names
- Silva, Ana
- Ana Martins Silva
Author identifiers
- Ciência ID
- 1116-6606-5CF5
- ORCID iD
- 0000-0002-1409-0831
Email addresses
- anamartins.neurologia@chporto.min-saude.pt (Professional)
Addresses
- Centro Hospitalar Universitario do Porto - Hospital de Santo António, Largo Abel Salazar, 441, Porto, Porto, Portugal (Professional)
Knowledge fields
- Medical and Health Sciences - Clinical Medicine - Clinical Neurology
Languages
Language | Speaking | Reading | Writing | Listening | Peer-review |
---|---|---|---|---|---|
Portuguese | Advanced (C1) | Advanced (C1) | Advanced (C1) | Advanced (C1) | |
English | Upper intermediate (B2) | Advanced (C1) | Advanced (C1) | Advanced (C1) | |
French | Intermediate (B1) | Advanced (C1) | Beginner (A1) | Intermediate (B1) | |
Italian | Intermediate (B1) | Intermediate (B1) | Intermediate (B1) |
Education
Degree | Classification | |
---|---|---|
2016/09 - 2016/12
Concluded
|
Management in health organizations (Outros)
AESE Business School, Portugal
|
|
2014/06
Concluded
|
Ciências Biomédicas (Doutoramento)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
"Funcionamento cognitivo em doentes com esclerose múltipla - estudo numa população portuguesa" (THESIS/DISSERTATION)
|
Aprovado com distinção |
2003/10/01 - 2004/06/30
Concluded
|
Neurology (Outros)
San Raffaelle Hospital, Italy
|
|
2004
Concluded
|
Neurology (Diploma de especialização)
Centro Hospitalar Universitário do Porto EPE, Portugal
|
|
1996
Concluded
|
Medicina (Licenciatura)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
|
16 |
Affiliation
Teaching in Higher Education
Category Host institution |
Employer | |
---|---|---|
2014 - Current | Invited Assistant Professor (University Teacher) | Universidade do Porto, Portugal |
Positions / Appointments
Category Host institution |
Employer | |
---|---|---|
2014 - Current | Neurology Consultant | Centro Hospitalar Universitário do Porto EPE, Portugal |
Centro Hospitalar Universitário do Porto EPE, Portugal | ||
2014 - Current | Member of Unit for Multidisciplinary Research in Biomedicine | Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal |
2009 - Current | Responsible for the Neuroimmunology Group | Centro Hospitalar Universitário do Porto EPE, Portugal |
2004 - Current | Member of Unit of Clinical Immunology | Centro Hospitalar Universitário do Porto EPE, Portugal |
2004 - Current | Member of Unit Corino de Andrade | Centro Hospitalar Universitário do Porto EPE, Portugal |
Others
Category Host institution |
Employer | |
---|---|---|
1999/01 - 2004/03 | Neurologist | Centro Hospitalar Universitário do Porto EPE, Portugal |
Projects
Grant
Designation | Funders | |
---|---|---|
2021 - Current | Covid-19 and neuroimmunological diseases study (cns-19): a retrospective non-interventional study for the evaluation of signs,
symptoms and clinical course of sars-cov-2 infection in patients with neuroimmune
098-defi-101-ce
Principal investigator
Centro Hospitalar Universitário do Porto EPE, Portugal
|
Ongoing
|
2021 - Current | Cadeias leves livres Kappa no diagnóstico da esclerose múltipla
008-DEFI/008
Principal investigator
Centro Hospitalar Universitário do Porto EPE, Portugal
|
Ongoing
|
2021 - Current | The role of dysbiosis in immune cell dysfunction and disease exacerbation in two model autoimmune diseases
177-DEFI/178
Principal investigator
Centro Hospitalar Universitário do Porto EPE, Portugal
|
Ongoing
|
2020 - Current | MuSC-19: Multiple Sclerosis and Covid-19
169-DEFI/170-CE
Principal investigator
Centro Hospitalar Universitário do Porto EPE, Portugal
|
Ongoing
|
2019 - Current | A validação clínica de um teste olfativo na esclerose múltipla
184-19 (150-defi/156-ces)
Principal investigator
|
Ongoing
|
2016 - Current | Genetic and epigenetic biomarkers of disease progression in multiple sclerosis portuguese patients
2016.057
Principal investigator
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
|
Ongoing
|
Contract
Designation | Funders | |
---|---|---|
2023/03/01 - 2026/02/28 | O labirinto genético da Polineuropatia Amiloidótica Familiar ATTRV30M: uma abordagem genómica
2022.01656.PTDC
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
Universidade do Porto Instituto de Investigação e Inovação em Saúde, Portugal |
Fundação para a Ciência e a Tecnologia
Ongoing
|
2010/05/01 - 2013/10/31 | Variabilidade fenotípica e genes modificadores na Polineuropatia Amiloidótica Familiar PAF ATTRV30M
PTDC/SAU-GMG/100240/2008
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
Universidade do Porto Instituto de Biologia Molecular e Celular, Portugal Centro Hospitalar Universitário de Santo António, Portugal |
Fundação para a Ciência e a Tecnologia
Concluded
|
Other
Designation | Funders | |
---|---|---|
2020 - Current | Doença desmielinizante inaugural em período de pandemia de SARS-COV-2
2020.216
Principal investigator
Centro Hospitalar Universitário do Porto EPE, Portugal
|
|
2019 - Current | O papel da disbiose intestinal nos surtos de doentes com esclerose múltipla
102-19 (083-defi/ 087-ces)
Principal investigator
Centro Hospitalar Universitário do Porto EPE, Portugal
|
Ongoing
|
2018 - Current | Impato do envelhecimento imunológico no desenvolvimento da esclerose múltipla
2018.113 (098 defi/ 097 ces)
Principal investigator
|
|
2017 - Current | Doenças do espetro da neuromielite óptica em portugal (NMOSD) - registo multicêntrico
2017.151
Principal investigator
|
|
2016 - Current | Reabilitação cognitiva - estudo clínico de intervenção: "multiple sclerosis rehabilitation protocol"
2016.068
Principal investigator
|
Ongoing
|
Outputs
Publications
Book |
|
Book chapter |
|
Journal article |
|
Activities
Oral presentation
Presentation title | Event name Host (Event location) |
|
---|---|---|
2021/11/25 | Evolução da Abordagem Terapêutica da Amiloidose | Explorers – Tegsedi transformado o cenário da amiloidose ATTRv
PTC Farmacêutica do Brasil
|
2021/11/18 | Cognition in MS patients |
Bristol Myers Squibb
|
2021/11/12 | Integração dos patient-reported outcomes na prática clinica |
Biogen
|
2021/10/29 | PAF – quando o puzzle faz sentido |
Sobi (Portugal)
|
2021/10/29 | Ponesimod - Um novo DMD oral de 1ª linha para o tratamento da esclerose múltipla |
Janssen (Portugal)
|
2021/05/28 | Tratamento de indução na Esclerose Múltipla |
Sociedade Portuguesa de Neurologia (Portugal)
|
2021/03/22 | Considerações para a escolha do ASO como opção terapêutica baseada em casos clínicos | Explorers
PTC Farmacêutica do Brasil
|
2021/02/21 | Neuro-Lupus: a problemática do envolvimento neurológico |
Unidade de Imunologia Clinica do Centro Hospitalar Universitário do Porto (Porto, Portugal)
|
2021/01/15 | Envolvimento neurológico das doenças sistémicas |
Unidade de Imunologia Clinica do Centro Hospitalar Universitário do Porto (Porto, Portugal)
|
2020/11/25 | hATTR a Portuguese Disease: a clinical case approach | Lux hATTR Multidisciplinar symposium
Alnylam Pharmaceuticals (Luxembourg)
|
2020/11/25 | Advances in disease management and monitoring of hATTR | Lux hATTR Multidisciplinar symposium
Alnylam Pharmaceuticals (Luxembourg)
|
2020/10/23 | Amiloidose ATTRh: importância de um diagnóstico e tratamento precoce | Simposium do 8º Congresso da SPEDNM
Alnylam Pharmaceuticals (Portugal)
|
2020/10/16 | A Evolução do Conceito NEDA e as suas limitações práticas | Brainstorm summit 2020
Biogen Idec (Lisboa, Portugal)
|
2020/07/18 | PAF: Como retardar a progressão da doença e melhorar a qualidade de vida dos doentes | Simposium do XXIX Congresso Brasileiro de Neurologia
PTC Farmacêutica do Brasil
|
2020/06/23 | Resultados do Ensemble plus | Moving Foward – Ocrelizumab: Perfusão de curta duração
ROCHE (Portugal)
|
2020/01/16 | Central Nervous system involvement | hATTR EU Preceptorship
Sociedade Portuguesa de Estudos de Doenças Neuromusculares (Porto, Portugal)
|
2020/01/16 | Neurological exam | hATTR EU Preceptorship
Sociedade Portuguesa de Estudos de Doenças Neuromusculares (Porto, Portugal)
|
2019/12/13 | MS treatment in patients planning a pregnancy | BRAIN STORM SUMMIT & IMAGING NETWORK 2019
Biogen Idec (Lisboa, Portugal)
|
2019/12/13 | Long-Term Safety: more than 130.000 patients treated | Ocrelizumab in focus
ROCHE (Porto, Portugal)
|
2019/11/19 | Brain Health - Time matters in MS | 12th Young Fellowship Course Oporto
Sanofi-Genzyme (Porto, Portugal)
|
2019/11/15 | Esclerose Múltipla: Da teoria à prática real | Simposium Sanofi-Genzyme, Congresso de Neurologia
Sanofi-Genzyme (Coimbra, Portugal)
|
2019/11/14 | Nova opção terapêutica: Inotersen | Simposium "Atualizações em Polineuropatia Amiloidótica Familiar - PAF", Congresso de Neurologia
Akcea Therapeutics (Coimbra, Portugal)
|
2019/10/02 | Imunomoduladores e infeção na Esclerose Múltipla | 16º Encontro Nacional de Atualização em Infecciologia
Serviço de Infeciologia do Centro Hospitalar Universitário do Porto (Porto, Portugal)
|
2019/09/11 | Espasticidade: porque os sintomas são a parte visível da doença para quem tem Esclerose Múltipla |
Almirall (Porto, Portugal)
|
2019/06/14 | Ocrelizumab: From Clinical Trials to Real World Experience | Sharing Experience Meeting
ROCHE (Porto, Portugal)
|
2019/04/06 | Biomarcadores: uma nova era na Esclerose Múltipla | IV EMin
Biogen Idec (Porto, Portugal)
|
2019 | A importância da Cognição no doente com EM | Brain Network - immersive learning (e-learning)
Biogen Idec
|
Supervision
Thesis Title Role |
Degree Subject (Type) Institution / Organization |
|
---|---|---|
2020 - Current | Epidemiological characterization of TTR-FAP patients diagnosed in Unidade Corino de Andrade
Supervisor of Ana do Carmo Ramalho Moreira Azevedo
|
Ciências Médicas (PhD)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
|
2019 - Current | Neuropsychological assessment in Multiple Sclerosis: the preditive value of neurodegenerative vision-related measures
Supervisor of Dália Maria Guedes Martins Meira
|
Ciências Médicas (PhD)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
|
2018 - Current | Polineuropatia Desmielinizante Inflamatória Crónica: Caracterização clínico-laboratorial e avaliação da incapacidade e impacto
funcional na prática clínica
Supervisor of André Daniel Aires Fernandes
|
Medicina (Master)
Centro Hospitalar Universitário do Porto EPE, Portugal
|
2017 - Current | Glycans as novel immunomodulators in Idiopathic Inflammatory Myopathies
Co-supervisor of Ana Cristina Cerveira Campar Almeida
|
Ciências Médicas (PhD)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
|
2017 - Current | Síndrome de Sjogren: quadro clínico e relação com as aquaporinas 4 e 5 e seus anticorpos
Co-supervisor of Mariana Brandão Marques Fernandes da Silva
|
Ciências Médicas (PhD)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
|
2019/10 - 2020/07 | MicroRNAs inflamatórios como Biomarcadores de Exacerbação na Esclerose Múltipla
Supervisor of Daniela Neves Silva
|
Bioquímica (Degree)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
|
2019/09 - 2020/07 | Valor Preditivo de um teste olfactivo na Esclerose Múltipla
Supervisor of Maria Clara Torres Cunha Carvalho
|
Medicina (Master)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
|
2019/09 - 2020/07 | O papel da disbiose intestinal na Esclerose Múltipla
Supervisor of Ana Rita Moreira de Castro
|
Medicina (Master)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
|
2013 - 2017/12/13 | Genetic susceptibility and immune dysfunction in Multiple Sclerosis
Co-supervisor of Andreia Manuela Teixeira Bettencourt Moreira
|
Ciências Biomédicas (PhD)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
|
2012 - 2017 | Internal doctor training in the specialization of Neurology
Supervisor of Ana Raquel Samões
|
Medicina (Specialization course)
Centro Hospitalar Universitário do Porto EPE, Portugal
|
2014/01/02 - 2014/03/30 | Internal doctor training in the specialization of Physical Medicine and Rehabilitation
Supervisor of Diogo Manuel Maia Couto Soares
|
Medicina (Specialization course)
Centro Hospitalar Universitário do Porto EPE, Portugal
|
2013/07/01 - 2013/09/30 | Internal doctor training in the specialization of Psychiatry
Supervisor of Vítor Filipe Oliveira Gonçalves Pimenta
|
Medicina (Specialization course)
Hospital de Magalhães Lemos EPE, Portugal
|
2006 - 2011 | Internal doctor training in the specialization of Neurology
Supervisor of Éster Coutinho
|
Medicina (Specialization course)
Centro Hospitalar Universitário do Porto EPE, Portugal
|
2005 - 2006 | Internal doctor training in the specialization of Neuroradiology
Supervisor of Pedro Pinto
|
Medicina (Specialization course)
Centro Hospitalar Universitário do Porto EPE, Portugal
|
Event organisation
Event name Type of event (Role) |
Institution / Organization | |
---|---|---|
2021/12 - Current | Multiple Sclerosis Academy 2021-2022 (2022/12)
Other (Member of the Scientific Committee)
|
Advance Health Education, Portugal |
2020/11 - 2021/01 | Course: "Imunologia para Neurologistas" (2020/11 - 2021/01)
Other (Co-organisor)
|
Grupo de Estudos de Esclerose Múltipla, Portugal |
2020/12/08 - 2020/12/08 | XV ANEM Symposium - Commemoration of the National Day of Multiple Sclerosis Patients (2020/12/08 - 2020/12/08)
Conference (President of the Organising Committee)
|
Centro Hospitalar Universitário do Porto EPE, Portugal |
2020/06 - 2020/10 | Course "Infecciologia para Neurologistas" (2020/06 - 2020/10)
Other (Member of the Organising Committee)
|
Grupo de Estudos de Esclerose Múltipla, Portugal |
2019/12 - 2019/12 | XIV ANEM Symposium - Commemoration of the National Day of Multiple Sclerosis Patients (2019/12/08)
Conference (President of the Organising Committee)
|
Event participation
Activity description Type of event |
Event name Institution / Organization |
|
---|---|---|
2021/10/28 - 2021/10/28 | Session moderator: EP Desmielinizantes (EP013-EP018) Cognição e Demência (EP03-EP036)
Symposium
|
Sociedade Portuguesa de Neurologia, Portugal
|
2021/10/13 - 2021/10/15 | 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Congress
|
European Committee for Treatment and Research in Multiple Sclerosis, Switzerland
|
2021/07/03 - 2021/07/03 | Session moderator: Are we ready to cure MS ? – Prof Mancardi
Symposium
|
Grupo de Estudos de Esclerose Múltipla, Portugal
|
2021/06/25 - 2021/06/26 | Peripheral Nerve Society 2021
Conference
|
Peripheral Nerve Society, United States
|
2021/06/19 - 2021/06/22 | Congress European Academy of Neurology
Congress
|
European Academy of Neurology, Austria
|
2021/04/17 - 2021/04/22 | 73rd Annual Meeting of the American Academy of Neurology
Congress
|
American Academy of Neurology, United States
|
2019/11/28 - 2019/11/30 | Board Moderator: "How many sarcoidosis? The great imitator!"
Meeting
|
Autoimmune disease international meeting
Centro Hospitalar Universitário do Porto EPE, Portugal
|
2019/09/11 - 2019/09/13 | 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and Annual Conference of
Rehabilitation in MS
Congress
|
35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and Annual Conference of
Rehabilitation in MS
European Committee for Treatment and Research in Multiple Sclerosis, Switzerland
|
2019/05/31 - 2019/06/01 | Board Moderator: "Diáspora e Esclerose Múltipla"
Meeting
|
Reunião da Primavera do Grupo de Estudos de Esclerose Múltipla |
2019/04/10 - 2019/04/14 | Board Moderator: Neuroimmunopsicology
Congress
|
CVI Congresso de Autoimunidade e XXV reunião Anual do NEDAI |
Jury of academic degree
Topic Role |
Candidate name (Type of degree) Institution / Organization |
|
---|---|---|
2021/07 | Gene Suppression Therapy in Hereditary Cerebellar Ataxias- a Systematic Review
Thesis Member
|
Carolina Inácio dos Santos (Master)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
|
2021/07 | Stroke Laterality: impact on the time to admission and acute treatment
President of the jury
|
Maria Beatriz Rodrigues Lagarteira (Master) |
2021/07 | Impacto do levante precoce pós-operatório na qualidade de vida dos doentes submetidos a drenagem de hematoma subdural crónico
President of the jury
|
Miguel Eduardo Cruz Fidalgo (Master)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
|
2021/06 | Efficacy of Vagus Nerve Stimulation and Ictael
President of the jury
|
Malaquias Barreto Laczkovits (Master)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
|
2021/01/27 | Exploring the role of astrocytes in the pathophysiology of multiple sclerosis
Thesis Member
|
Sofia Pereira das Neves (PhD)
Universidade do Minho, Portugal
|
2020/07 | A associação entre fenómeno de Raynaud e enxaqueca: prevalência e preditores clínicos.
(Thesis) Main arguer
|
Raquel Ferreira de Oliveira (Master)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
|
2020/07 | Epidemiologia e Abordagem dos Traumatismos Crânio-encefálicos em Países com Sistema Nacional de Saúde: Revisão Bibliográfica
Epidemiologia e Abordagem dos Traumatismos Crânio-encefálicos em Países com Sistema Nacional de Saúde
President of the jury
|
Alexandra Santos Machado (Master)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
|
2020/07 | Comorbilidades Psiquiátricas na Epilepsia Temporal Mesial com Esclerose do Hipocampo
President of the jury
|
João Diogo Pereira Barreira (Master)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
|
2020/07 | Epilepsy and an convulsant therapy in glioblastoma prognosis
President of the jury
|
Carolina Isabel Vieira Bastos Salgado Coutinho (Master)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
|
2019 | Complicações da Ventilação Não Invasiva na Insuficiência Respiratória Aguda: Casuística de uma Unidade de Cuidados Intermédios
e Protocolo de Abordagem
President of the jury
|
Sara Alves Araujo (Master)
Centro Hospitalar Universitário do Porto EPE, Portugal
|
2019 | Perioperative Management of Diabetes Mellitus. A Review
President of the jury
|
Mariana Moreira Azevedo (Master) |
2018/07 | Hidrocefalia de pressão normal clínica e resposta à derivação ventriculoperitoneal
President of the jury
|
Francisco de Campos Paiva Ferreira Silva (Master)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
|
2018/07 | Agentes biológicos no tratamento da espondiloartrite axial: impacto na actividade da doença e na qualidade de vida dos doentes
President of the jury
|
Susana Maria Cardoso Moreira (Master)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
|
2018/07 | Prognóstico cirúrgico em epilepsia - retirada da medicação
President of the jury
|
Rebeca Isabel Barreto Gomes (Master)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
|
2018/07 | Efeitos do exercicio fisico na insuficiência cardiaca com fração de ejeção preservada
President of the jury
|
Mariana Lima Bragança (Master)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
|
2018/07 | Polineuropatia amiloidótica familiar: atingimento cardiovascular após transplante hepático
President of the jury
|
Diana patricia Pereira Coelho (Master)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
|
2018/04/09 | Myasthenia Gravis in the north of Portugal: epidemiological, clinical and serologicalstudy and immunopathology of the thymus
(Thesis) Arguer
|
Maria Ernestina Azevedo Moreira dos Santos (PhD)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
|
2017/12/22 | Neural correlates of theory of mind impairment in multiple sclerosis
(Thesis) Arguer
|
Sónia Raquel Marques Batista (PhD)
Hospitais da Universidade de Coimbra, Portugal
|
2017/07 | O paradoxo nutricional - a coexistência de obesidade e desnutrição
President of the jury
|
Ana Rita Rodrigues Teixeira (Master)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
|
2017/07 | Variabilidade na prevalência da codificação da asma nos cuidados de saúde primários na região Norte - uma comparação com a
diabetes
President of the jury
|
Ricardo Jorge Neves dos Santos Teixeira Pinto (Master)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
|
2017/07 | Revisão de glioblastomas multiformes operados no CHP entre 2010 e 2014: caracterização da amostra e estudos dos factores de
prognóstico
(Thesis) Arguer
|
Penélope Cristina Correia (Master)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
|
2017/07 | Estudo retrospectivo e caracterização dos doentes operados a oligodendrogliomas no Centro Hospitalar do Porto de Janeiro de
2000 a Dezembro de 2010.
(Thesis) Arguer
|
Andreia Sofia Dias Coutinho (Master)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
|
2015/12/21 | Impact of mechanotransduction in the context of central nervous system diseases
(Thesis) Arguer
|
Daniela Nogueira da Rocha Mar (PhD)
Universidade do Porto Faculdade de Engenharia, Portugal
|
2010/07 | Miopatia induzida por Estatinas
(Thesis) Arguer
|
Renata de Paola Chequer (Other)
Centro Hospitalar Universitário do Porto EPE, Portugal
|
Committee member
Activity description Role |
Institution / Organization | |
---|---|---|
2021/09/01 - Current | Representative of Portuguese Society of Neurology as Institutional member on the EAN Scientific Panel of Neuroimmunology
Member
|
European Academy of Neurology, Austria |
2021 - Current | Principal Investigator of GAVOTTE: A phase IIIB multicentre, randomized, double-blind, controlled study to evaluated the efficacy,
safety and pharmacokinetics of a higher dose of ocrelizumab in adults with primary progressive multiple sclerosis
Other
|
|
2021 - Current | Principal Investigator of ENhance: A Study To Evaluate The Efficacy AnD Safety Of Fenebrutinib Compared With Teriflunomide
In relapsing multiple sclerosis
Other
|
|
2021 - Current | Principal Investigator of EVOLUTION: A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis
Other
|
|
2021 - Current | Principal Investigator of FENtrepid: A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab
In Adult Participants With Primary Progressive Multiple Sclerosis
Member
|
|
2020/10 - Current | Sub-investigator of CHAMPION5 (Protocol ALXN1210-MG-306) - A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter
Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia
Gravis
Other
|
|
2020/06 - Current | Principal Investigator and National Cordenator of ORATORIO-HAND (Protocol WA40404) - A phase IIIb multicenter, randomized,
double-blind, placebo-controlled study to evaluate the efficacy and safety of Ocrelizumab in assaults with primary progressive
Multiple Sclerosis
Other
|
|
2020 - Current | Sub-investigator of NEURO-TTRansform - A Study to Evaluate the Efficacy and Safety of AKCEA-TTR-LRx in Participants With Hereditary
Transthyretin-Mediated Amyloid Polyneuropathy
Member
|
|
2020 - Current | Member of Scientific Committee of the working group in the area "Inflammatory and Demyelinating Diseases" of the Portuguese
Society of Neurology
Member
|
|
2020 - Current | Principal Investigator of ARTIOS and and National Coordinating Investigator: A phase 4 single arm, prospective, multicenter,
open label study to evaluated ofatumumab treatment effectiveness and patient report outcomes in patients with relapsing multiple
sclerosis transitioning from dimethyl fumarate or fingolimod therapy
Member
|
|
2019/12 - Current | Sub-Investigator of Eidos AG10-301 – A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety
of AG10 in Subjects with Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTRIBUTE-CM Trial)
Other
|
|
2019/04 - Current | Sub-Investigator of HELIOS-A – A Phase 3 Global, RANDOMIZED, OPEN-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02
in Patients with Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)
Other
|
|
2019 - Current | Expert collaborating in the elaboration of the NOC on Prevention and Treatment of Vitamin D Deficiency
Member
|
Direção-Geral de Saúde, Portugal |
2019 - Current | Principal Investigator of OPTIMUM-LT – Multicenter, Non-comparative Extension to Study AC-058B301, to Investigate the Long-term
Safety, Tolerability, and Control of Disease of Ponesimod 20 mg in Subjects With Relapsing Multiple Sclerosis (Phase III Trial)
Other
|
|
2019 - Current | Principal Investigator of ALITHIOS – An Open-label, Single Arm, Multi-center Extension Study Evaluating Long-term Safety,
Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis (Phase III Trial)
Other
|
|
2018/09 - Current | Principal Investigator and National Coordinating Investigator of CLARIFY – A 2-year Prospective Study to Assess Health-related
Quality of Life in Subjects with Highly-active Relapsing Multiple Sclerosis Treated with Mavenclad® (Phase IV Trial)
Other
|
|
2018/07 - Current | Principal Investigator of TeriLIVE-QoL Observational, non-interventional Portuguese study to assess quality of life in patients
with Relapsing-Remitting Multiple Sclerosis treated with teriflunomide 14 mg in a real clinical setting (Phase IV Trial)
Other
|
|
2018/01 - Current | Portuguese Representative of Multiple Sclerosis International Federation (IMSB)
Member
|
|
2018 - Current | Principal Investigator of A Phase 1, open-label study of intravenous (IV) PRX004 as a single agent in subjects with hereditary
amyloid transthyretin (hATTR) amyloidosis
Other
|
|
2017/10 - Current | Principal Investigator of ENSEMBLE – An Open Label, single-arm study to evaluate the effectiveness and safety of Ocrelizumab
in patients with early stage relapsing remitting multiple sclerosis (Phase III Trial)
Other
|
|
2014/05 - Current | Sub-Investigator of APOLLO – A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate
the Efficacy and Safety of ALN-TTR02 in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy)
(Phase III Trial)
Other
|
|
2014 - Current | Principal Investigator of Protocol 109MS408 A multicenter, open-label study evaluating the effectiveness of oral tecfidera
(Dimethyl Fumarate) on MS disease activity and patient-report outcomes in subjects with relapsing-remitting multiple sclerosis
in the real-world setting (Protec) (Phase IV Trial)
Other
|
|
2013/11 - Current | Principal Investigator of Protocol CBAF312A2304 – A multicenter, randomized, double blinded, parallel-group, placebo-controlled
variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary multiple
scleroris (Phase III Trial)
Other
|
|
2013/11 - Current | Sub-Investigator of ALN-TTR02-003 – A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety,
Clinical Activity, and Pharmacokinetis of ALN-TTR02 in Patients with Familial Amyloidotic Polyneuropathy Who have Previously
Received ALN-TTR02 (Phase II Trial)
Other
|
|
2013 - Current | Principal Investigator of PASSAGE Long-term, prospective, non-interventional, multinational and parallel cohort study
that monitors safety in MS patients who have recently started treatment with Fingolimod, once daily, or treated with another
approved disease-modifying therapy (TMD) (Phase IV Trial)
Other
|
|
2013 - Current | Principal Investigator of GYLENIA Multinational registration of exposure to Gilenya during pregnancy in multiple sclerosis
(Phase IV Trial)
Other
|
|
2012/09 - Current | Sub-Investigator of A Phase 2, Open-Label, Multi-Dose, Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics,
and Pharmacodynamics of Intravenous Infusions of ALN-TTR02 in Patients with TTR Amyloidosis (Phase II Trial)
Other
|
|
2010/03 - Current | Member of Group Technical Validation Therapy and Good Clinical Practice in Multiple Sclerosis of General Health Directorate
(DGS)
Member
|
Direção-Geral de Saúde, Portugal |
2009 - Current | Scientific-technical adviser of the National Association of Multiple Sclerosis (ANEM)
Member
|
|
2017/01 - 2021/10/01 | Boarding Member of Grupo de Estudos de Esclerose Múltipla (GEEM)
Member
|
|
2017/02 - 2021/01 | Principal Investigator of ASCLEPIOS – A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy
and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis (Phase III Trial)
Other
|
|
2015/12 - 2021 | Sub-Investigator of ALN-TTR02-006 – A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy
of Patisiran in Patients with Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Clinical Study with Patisiran
(Phase III Trial)
Other
|
|
2016 - 2020/01 | Principal Investigator of OPTIMUM (Oral Ponesimod versus Teriflunomide In relapsing MUltiple sclerosis) – Multicenter, randomized,
double-blind, parallel-group, active controlled, superiority study to compare the efficacy and safety of ponesimod to teriflunomide
in subjects with relapsing multiple sclerosis (Phase III Trial)
Other
|
|
2018/05 - 2020 | Principal Investigator of PRX004-101 – A Phase 1, Open-label, Dose Escalation Study of Intravenous PRX004 in Subjects with
Amyloid Transthyretin (ATTR) Amyloidosis (Phase I Trial)
Other
|
|
2017 - 2020 | Principal Investigator of PLENO – Open-Label, Randomized, 2 arm, Active Comparator Study to Evaluate Safety and Tolerability
in Portuguese Patients with Relapsing Remitting Multiple Sclerosis (RRMS) Transitioning from Standard-of-Care Subcutaneous
Interferon Therapy to Peginterferon Beta-1ª (PLEGRIDYTM) (Phase III Trial)
Other
|
|
2015/04 - 2020 | Sub-Investigator of ISIS 420915-CS3 – An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915
in Patients with Familial Amyloid Polyneuropathy (FAP) (Phase III Trial)
Other
|
|
2013/07 - 2020 | Sub-Investigator of ISIS 420915-CS2 – A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy
and Safety of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy (Phase II/III Trial)
Other
|
|
2012/03 - 2018/12 | Principal Investigator of ORATORIO A Phase III, multicenter, randomized, parallel-group, double-blinded, placebo-controlled
study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis WA25046 (Ocrelizumab,
Roche) (Phase III Trial)
Other
|
|
2016 - 2018 | Sub-Investigator of IMPRESS The impact of depression in patients with Multiple Sclerosis who started treatment with interferon-concrete
1a IM (Avonex) (Phase IV Trial)
Other
|
|
2015 - 2018 | Principal Investigator of LIBERATE – A Multicenter, Multinational, Observational Study to Collect Information on Safety and
to Document the Drug Utilization of Fampyra® When Used In Routine Medical Practice (LIBERATE) (Phase IV Trial)
Other
|
|
2015 - 2016 | Principal Investigator of PROADHER Prospective observational study of adherence to therapy in patients with Relapsing-Remitting
Multiple Sclerosis using Rebismart (Phase IV Trial)
Other
|
|
2014 - 2016 | Principal Investigator of JUSTIFY – Epidemiology and retropective assessment of the seroprevalence of JC vírus Antibody in
the Portuguese Relapsing Remitting MS patient population (Phase IV Trial)
Other
|
|
2013 - 2016 | Principal Investigator of CogniPlus Prospective study to evaluate the association between physical activity and cognitive
function in patients with Relapsing-Remitting Multiple Sclerosis undergoing Betaferon treatment® (Phase IV)
Other
|
|
2013 - 2015 | Member of the Multiple Sclerosis Working Group of National Pharmacy and Therapeutics Committee (INFARMED)
Member
|
Infarmed Autoridade Nacional do Medicamento e Produtos de Saúde IP, Portugal |
2012/10 - 2015 | Principal Investigator of SOLAR – A three-arm, randomized, double-blind, placebo-controlled, multicenter, phase II study to
evaluate the efficacy of VIGANTOL® oil as add-on therapy in subjects with Relapsing-Remitting Multiple Sclerosis receiving
treatment with 44µ tiw of Rebif® (Phase II Trial)
Other
|
|
2008 - 2014 | Principal Investigator of TYGRIS-ROW Observational, prospective, open, international multicenter study to assess the safety
of TYSABRI® (NATALIZUMAB) in the treatment of Relapsing-Remitting Multiple Sclerosis (Phase IV Trial)
Other
|
|
2012/06 - 2013/07 | Principal Investigator and National Coordinating Investigator of A Multicenter, Randomized, Double-Blind, Placebo-Controlled
Study, Followed by an Open-Label Treatment Period, to Assess the Effect of Fampridine-PR 10 mg Twice Daily on Improvement
in Muscle Strength, Mobility, and Physical Fatigue in Multiple Sclerosis (Phase IV Trial)
Other
|
|
2007 - 2013 | Sub-Investigator of Safety and Efficacy of orally Fx-1006 in patients with familial amyloid polyneuropathy (FAP): a phase
II/III, randomized, doulble blind , placebo controlled study (Phase II/III Trial)
Other
|
|
2010/12 - 2011/04 | Principal Investigator of A 4-month, open-label, multi-center study to explore tolerability and safety and health outcomes
of FTY720 in patients with relapsing forms of multiple sclerosis - CFTY720D2316 (Phase IV Trial)
Other
|
|
2010 - 2011 | Sub-Investigator of A Phase 1, Randomized, Single-Blind, Placebo-Controlled, Dose Escalation Trial to Evaluated the Safety
and tolerability of a single Dose of Intravenous ALN-TTR01 in Patients with TTR Amyloidosis (Phase IV Trial)
Other
|
|
2006 - 2011 | Principal Investigator of Global Adherence Project (GAP) Observational, international and multicenter study with the
objective of evaluating the rate of adherence to disease-modifying therapies in patients with relapsing-remitting multiple
sclerosis (Phase IV Trial)
Other
|
|
2010 - 2010 | Principal Investigator of BEACON (Phase IV Trial)
Other
|
|
2009 - 2010 | Representative of the Portuguese Neurology Society on the panel of the European Federation Neurological Societies (EFNS)
Member
|
|
2009 - 2010 | Sub-Investigator of An Open-Label Extension of Study Fx-005 Evaluating Long-Term Safety and Clinical Outcomes of Fx-1006A
in patients with Transthyretin Amyloid Polyneuropathy (Phase IV Trial)
Other
|
|
2008 - 2008 | Principal Investigator of START (Phase IV Trial)
Other
|
|
2006 - 2008 | MGTX – Tymectomy trial in non-thymatous myasthenia gravis patients receiving prednisolone (Phase III Trial)
Other
|
|
2005 - 2007 | Principal Investigator of Cogni MS. Observational Study to Assess Cognition in Patients with early Multiple Sclerosis Schering
AG- (Phase IV Trial).
Other
|
|
2001 - 2001 | Sub-Investigator of CL3-04200-006-PRT (Phase IV Trial)
Other
|
Course / Discipline taught
Academic session | Degree Subject (Type) | Institution / Organization | |
---|---|---|---|
2007/09 - Current | Clinical Neurosciences | Medicina (Mestrado integrado) | Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal |
2007/09 - Current | Neurological Semiology | Medicina (Mestrado integrado) | Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal |
2019/06 - 2019/10 | Infectiology for Neurologists | Medicina (Outros) | Centro Hospitalar Universitário do Porto EPE, Portugal |
2003 - 2006 | Neurophysiology and Neuromuscular Physiology | Instituto Politécnico de Saude do Norte Escola Superior de Saúde do Vale do Ave, Portugal | |
2004 - 2005 | Neurophysiology of Communication | Ciências da Fala e da Audição (Mestrado) | Universidade de Aveiro, Portugal |
Journal scientific committee
Journal title (ISSN) | Publisher | |
---|---|---|
2019 - Current | Multiple Sclerosis and Related Disorders (2211-0348) | Elsevier |
2012 - Current | Sinapse (2184-4240) |
Other jury / evaluation
Activity description | Institution / Organization | |
---|---|---|
2020/11 - 2020/11 | Jury element of the Prize "Professor António Flores", Neurology Congress | |
2020 - 2020 | Jury element of the Prize "Esclerose Múltipla para internos", 4th edition EMin |
Distinctions
Award
2021 | Prémio para melhor comunicação oral da Reunião de Primavera/Verão do Grupo de Estudos de Esclerose Múltipla 2021
Grupo de Estudos de Esclerose Múltipla, Portugal
|
2021 | Prémio António Flores para o melhor e-poster do Congresso de Neurologia de 2021
Sociedade Portuguesa de Neurologia, Portugal
|
2019 | Orlando Leitão
Sociedade Portuguesa de Neurologia, Portugal
|
2017 | Orlando Leitão |
2015 | Best Oral Communication on the 3th International Porto Congress on MS |
2012 | Sollari Allegro |
2011 | Investigator Award on Neuropathies |
2010 | António Flores |
2009 | Investigator Award by the EFNS Scientist Panel on Genetics and Metabolic Disorders |
2007 | Clinical investigator Award on the meeting of the Portuguese Society of Human Genetics |
2006 | International Society for Behçet Disease Young Investigator |
2001 | Serono of Demyelinating Diseases |
2001 | Novartis of Neurology |
2001 | Serono of Neurology/Demyelinating Diseases |
1996 | Santa Casa da Misericórdia
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
|